SCHEMBL4873352

SCHEMBL4873352

Nc1ccc(S(=O)(=O)NOC2CCCC2)cc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
ALDH1A1 P00352 5/20 0.47
POLB P06746 2/20 0.47
PKM P14618 1/20 0.47
FFAR4 Q5NUL3 1/20 0.45
MAPT P10636 5/20 0.44
RAB9A P51151 1/20 0.44
TDP1 Q9NUW8 4/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
WNK1 Q9H4A3 2/20 0.41
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TSHR P16473 1/20 0.40
CA9 Q16790 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 2/20 0.39
CYP19A1 P11511 1/20 0.39
GPR55 Q9Y2T6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867769 0.84 KDM4E (0.44) KMT2AMEN1ALDH1A1POLBPKM
SCHEMBL4869134 0.81 CA2 (0.56) KMT2AMEN1ALDH1A1HTTCA9
SCHEMBL14074428 0.78 BRD4 (0.38) KMT2AALDH1A1POLBPKMMAPT
SCHEMBL4862422 0.75 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1POLBPKM
SCHEMBL4863860 0.74 POLB (0.48) KMT2AALDH1A1POLBPKMTDP1
SCHEMBL11280979 0.73 VCAM1 (0.67) KMT2AMEN1ALDH1A1POLBPKM
SCHEMBL4865850 0.72 PKM (0.48) KMT2AMEN1POLBPKMMAPT
SCHEMBL11094292 0.71 FFAR4 (0.81) KMT2AMEN1ALDH1A1POLBPKM
SCHEMBL1564742 0.70 KMT2A (0.67) KMT2AMEN1ALDH1A1POLBPKM
SCHEMBL30932792 0.70 KMT2A (0.67) KMT2AMEN1ALDH1A1POLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419967-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-02 US disclosed
US-7419967-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-02 US disclosed
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
EP-1086076-B1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2004-12-22 EP disclosed
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease HALE MICHAEL ROBIN (US) 2004-05-20 US disclosed
US-6613743-B2 Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-02 US disclosed
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-04-25 US disclosed
EP-1086076-A1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2001-03-28 EP disclosed
WO-1999065870-A2 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP KMT2A 860/4885MEN1 4380/4885ALDH1A1 1841/4885
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP KMT2A 860/4885MEN1 4380/4885ALDH1A1 1841/4885
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP KMT2A 860/4885MEN1 4380/4885ALDH1A1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.